Economic burden of acute coronary syndrome in South Korea: a national survey

Kim, Jinhyun; Lee, Eun-Hee; Lee, Tae-Jin; Sohn, Aeree

doi:10.1186/1471-2261-13-55

Cited by 19 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular diseases may be increased continuously due to increase in the prevalence of metabolic syndrome over time, since the aging index in Korea is expected to rise from 67.7% in 2010 to 213.8% in 2030. 24 , 25 Therefore, in Korea, ACS is expected to become one of the most common conditions associated with ischemic heart disease, and ACS-related costs will be likely to increase steadily. It is essential to manage ACS early and effectively to prevent ACS-associated mortality and morbidity.…”

Section: Discussionmentioning

confidence: 99%

Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea

Byeon

Yang

Choi

2016

TCRM

View full text Add to dashboard Cite

BackgroundAcute coronary syndrome (ACS) is a fatal cardiovascular disease caused by atherosclerotic plaque erosion or rupture and formation of coronary thrombus. The latest guidelines for ACS recommend the combined drug regimen, comprising aspirin, P2Y12 inhibitor, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and statin, at discharge after ACS treatment to reduce recurrent ischemic cardiovascular events. This study aimed to examine prescription patterns of secondary prevention drugs in Korean patients with ACS after hospital discharge, to access the appropriateness of secondary prevention drug therapy for ACS, and to evaluate whether to persistently use discharge medications for 18 months.MethodsThis study was retrospectively conducted with the patients who were discharged from the tertiary hospital, located in South Korea, after ACS treatment between September 2009 and August 2013. Data were collected through electronic medical record.ResultsAmong 3,676 patients during the study period, 494 were selected based on inclusion and exclusion criteria. The regimen of aspirin + clopidogrel + β-blocker + angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker + statin was prescribed to 374 (75.71%) patients with ACS at discharge. Specifically, this regimen was used in 177 (69.69%) unstable angina patients, 44 (70.97%) non-ST-segment elevation myocardial infarction patients, and 153 (85.96%) ST-segment elevation myocardial infarction patients. Compared with the number of ACS patients with all five guideline-recommended drugs at discharge, the number of ACS patients using them 12 (n=169, 34.21%) and 18 (n=105, 21.26%) months after discharge tended to be gradually decreased.ConclusionThe majority of ACS patients in this study received all five guideline-recommended medications at discharge from the hospital. However, the frequency of using all of them had been gradually decreased 3, 6, 12, and 18 months after discharge compared with that at discharge. Careful monitoring of adherence on ACS secondary prevention medications may help improve the outcomes of ACS patients in terms of recurrent ischemic cardiovascular events.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea

Byeon

Yang

Choi

2016

TCRM

View full text Add to dashboard Cite

show abstract

“…According to the Korean Statistical Information Service (KOSIS), the number of deaths due to AMI (I21) was 19.6 out of every 100,000 Koreans in 2012 [ 3 ]. Also, while the AMI-associated mortality has gradually decreased, the prevalence of AMI is on the rise due to improvement in the early detection and treatment of AMI [ 4 ]. AMI has a heavy socioeconomic burden.…”

Section: Introductionmentioning

confidence: 99%

Recent Trends in Economic Burden of Acute Myocardial Infarction in South Korea

Seo

Yoon

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

In 2010, ischemic heart disease was the leading cause of disability-adjusted life-years (DALYs) worldwide. More specially, the prevalence of acute myocardial infarctions (AMI) is increasing in the aged population as mortality decreases; South Korea is no exception. This study aims to examine the economic burden of AMI in the Korean population between 2007 and 2012. AMI-related costs were assessed from a societal perspective. A prevalence-based cost-of-illness framework was used for this analysis. The subjects included all South Koreans with AMI-related ICD-10 codes (I21, I22, I23, I25.0, and I25.1). Data on direct (medical and non-medical) costs and indirect (productivity loss due to AMI-associated morbidity and mortality) costs were collected from the Korean National Health Insurance Service’s claims data. The human capital approach was used to calculate indirect costs. The total estimated cost of AMI in 2012 was $1,177,649,323 USD. The majority (52%) of this amount was made up of medical costs, followed by productivity losses due to mortality and morbidity (42% of annual cost). Although the total cost declined by approximately 18% compared to 2007 ($1,427,643,854 USD), the cost of AMI in the over 60 age group amounted to 47% of the total cost of AMI in 2012. AMI led to a high economic burden in 2012. This study, which identified not only the size, but also the trends of AMI-related costs, will provide information to evaluate effects of governmental health projects and the effective allocation of public research funds.

show abstract

“…The study also showed that despite a reduction in the percentage of the CVDs mortality cost after the HTP, this reduction was not statistically signi cant compared to that before the HTP, which is not consistent with the ndings of most studies in developed countries. In European countries, more than 60% of the total costs of CVDs attributed to the hospitalization (34,35), while in other studies, it was reported that just about 23% of CVDs costs attributed to the mortality costs in the UK (22) and about 33% in South Korea (36). One of the reasons for this may be due to the low mean age of CVDs mortality and morbidity in developing countries, such as Iran (37).…”

Section: Discussionmentioning

confidence: 99%

Economic Burden of Cardiovascular Diseases Before and After the Iran’s Health Transformation Plan: A Cross-Sectional Study on Referral Hospital in the North-West of Iran

Alipour

Zandian

Yazdi‐Feyzabadi

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundDifferent countries have set different policies to control and decrease the costs of Cardiovascular Diseases(CVDs). Iran aiming reducing the economic burden of different disease by a recent reform from named as health transformation plan(HTP). This study aimed to examine economic burden of CVDs before and after of HTP, MethodsThis cross-sectional study was conducted on 600 patients with CVDs, who were randomly selected from a specialized cardiovascular hospital in the north-west of Iran. Direct and indirect costs of CVDs were calculated using cost of illness and human capital approaches. Data were collected using a researcher-made checklist obtained from several sources including structured interviews, the Statistical Center of Iran, Iran's Ministry of Cooperatives, Labor, and Social Welfare, central bank of the Iran, and the data of global burden of disease obtained from the Institute for Health Metrics and Evaluation to estimate direct and mortality costs. All costs were calculated in Iranian Rials(IRR). ResultsTotal costs of CVDs were about 5571 and 6700 billion IRR before and after the HTP, respectively. More than 62% of the total costs of CVDs accounted for premature death before (64.89%) and after(62.01%) the HTP. The total hospitalization costs of CVDs was significantly increased after the HTP (p=0.038). In both times, surgical services and visiting had the highest and lowest share of hospitalization costs, respectively. The OOP expenditure decreased significantly and reached from 54.2% to 36.7%. All hospitalization costs, except patients' OOP expenditure, were significantly increased after the HTP about 1.3 times. Direct non-medical costs reached from 2.4 to 3.3 billion before and after the HTP, respectively. ConclusionThe economic burden of CVDs after the HTP increased in the north-west of Iran due to the increase of all direct and indirect costs, except the OOP expenditure. Non-allocation of defined resources, which coincided with the international and national political and economic challenges in Iran, led to

show abstract

Economic burden of acute coronary syndrome in South Korea: a national survey

Cited by 19 publications

References 22 publications

Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea

Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea

Recent Trends in Economic Burden of Acute Myocardial Infarction in South Korea

Economic Burden of Cardiovascular Diseases Before and After the Iran’s Health Transformation Plan: A Cross-Sectional Study on Referral Hospital in the North-West of Iran

Contact Info

Product

Resources

About